Florentine Hilbers
Adaptive immune signature in HER2-positive breast cancer in NCCTG (Alliance) N9831 and NeoALTTO trials
Chumsri S, Holmes E, Di Cosimo S, Werner O, Huober J, Dueck A, Sotiriou C, Saura C, Moreno-Aspitia A, Knutson K, Perez E, Van Dooren V, Hilbers F, Carey L, Li Z, Serie D, Norton N, Mashadi-Hossein A, Tenner K, Brauer H, Warren S, Danaher P, Colon-Otero G, Partridge A, Thompson E. Adaptive immune signature in HER2-positive breast cancer in NCCTG (Alliance) N9831 and NeoALTTO trials. NPJ Breast Cancer 2022; 8:68.
24.05.2022Adaptive immune signature in HER2-positive breast cancer in NCCTG (Alliance) N9831 and NeoALTTO trials
24.05.2022NPJ Breast Cancer 2022; 8:68
Chumsri Saranya, Holmes Eileen, Di Cosimo Serena, Werner Olena, Huober Jens, Dueck Amylou C, Sotiriou Christos, Saura Cristina, Moreno-Aspitia Alvaro, Knutson Keith L, Perez Edith A, Van Dooren Veerle, Hilbers Florentine, Carey Lisa A, Li Zhuo, Serie Daniel J, Norton Nadine, Mashadi-Hossein Afshin, Tenner Kathleen, Brauer Heather Ann, Warren Sarah, Danaher Patrick, Colon-Otero Gerardo, Partridge Ann H, Thompson E Aubrey
Tumor Cellularity and Infiltrating Lymphocytes (CelTIL) as a Survival Surrogate in HER2-Positive Breast Cancer
Chic N, Prat A, Huober J, Saura C, Di Cosimo S, Láng I, de Azambuja E, Wang Y, Hilbers F, Fumagalli D, Salgado R, Nuciforo P, Luen S, Loi S. Tumor Cellularity and Infiltrating Lymphocytes (CelTIL) as a Survival Surrogate in HER2-Positive Breast Cancer. J Natl Cancer Inst 2021
31.03.2021Tumor Cellularity and Infiltrating Lymphocytes (CelTIL) as a Survival Surrogate in HER2-Positive Breast Cancer
31.03.2021J Natl Cancer Inst 2021
Chic Nuria, Prat Aleix, Huober Jens, Saura Cristina, Di Cosimo Serena, Láng István, de Azambuja Evandro, Wang Yingbo, Hilbers Florentine, Fumagalli Debora, Salgado Roberto, Nuciforo Paolo, Luen Stephen J, Loi Sherene
An RB-1 loss of function gene signature as a tool to predict response to neoadjuvant chemotherapy plus anti-HER2 agents: a substudy of the NeoALTTO trial (BIG 1-06)
Risi E, Di Leo A, Biganzoli L, Sotiriou C, Vitale S, Boccalini G, Romagnoli D, Huober J, Di Cosimo S, Hilbers F, Guarducci C, Bonechi M, McCartney A, Migliaccio I, Benelli M, Biagioni C, Malorni L. An RB-1 loss of function gene signature as a tool to predict response to neoadjuvant chemotherapy plus anti-HER2 agents: a substudy of the NeoALTTO trial (BIG 1-06). Ther Adv Med Oncol 2019; 11:1758835919891608.
11.12.2019An RB-1 loss of function gene signature as a tool to predict response to neoadjuvant chemotherapy plus anti-HER2 agents: a substudy of the NeoALTTO trial (BIG 1-06)
11.12.2019Ther Adv Med Oncol 2019; 11:1758835919891608
Risi Emanuela, Di Leo Angelo, Biganzoli Laura, Sotiriou Christos, Vitale Stefania, Boccalini Giulia, Romagnoli Dario, Huober Jens, Di Cosimo Serena, Hilbers Florentine, Guarducci Cristina, Bonechi Martina, McCartney Amelia, Migliaccio Ilenia, Benelli Matteo, Biagioni Chiara, Malorni Luca
Plasma miRNA Levels for Predicting Therapeutic Response to Neoadjuvant Treatment in HER2-positive Breast Cancer: Results from the NeoALTTO Trial
Di Cosimo S, Verderio P, Apolone G, de Braud F, Piccart M, Baselga J, Huober J, Izquierdo M, de la Pena L, de Azambuja E, Hilbers F, Iorio M, Tiberio P, Pizzamiglio S, Appierto V, Daidone M. Plasma miRNA Levels for Predicting Therapeutic Response to Neoadjuvant Treatment in HER2-positive Breast Cancer: Results from the NeoALTTO Trial. Clin Cancer Res 2019; 25:3887-3895.
27.02.2019Plasma miRNA Levels for Predicting Therapeutic Response to Neoadjuvant Treatment in HER2-positive Breast Cancer: Results from the NeoALTTO Trial
27.02.2019Clin Cancer Res 2019; 25:3887-3895
Di Cosimo Serena, Verderio Paolo, Apolone Giovanni, de Braud Filippo G, Piccart Martine, Baselga José, Huober Jens, Izquierdo Miguel, de la Pena Lorena, de Azambuja Evandro, Hilbers Florentine, Iorio Marilena V, Tiberio Paola, Pizzamiglio Sara, Appierto Valentina, Daidone Maria Grazia